Ophthalmic Bevacizumab & CRISPR-Based Gene Therapy Among Latest EU Filings

Investigational drugs from Outlook Therapeutics and Vertex/CRISPR could become first-of-their-kind products if they win marketing approval.

CRISPR/Cas9 allows for precise, directed changes to genomic DNA • Source: Shutterstock

The European Medicines Agency has begun reviewing Outlook Therapeutics’s EU marketing authorization application (MAA) for what could become the first on-label ophthalmic formulation of bevacizumab (ONS-5010) to treat wet age-related macular degeneration (wet AMD).

In addition, the agency has accepted for review MAAs for exagamglogene autotemcel (exa-cel), Vertex Pharmaceuticals/CRISPR Therapeutics’ CRISPR/Cas9 gene...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography